Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

A new generation of novel cannabinoid compounds have been developed as marijuana substitutes to avoid drug control laws and cannabinoid blood tests. 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liability. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Discriminative stimulus effects were tested in rats trained to discriminate Δ 9 -tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (ED 50 = 1.1 mg/kg) and MDMB-CHIMICA (ED 50 = 0.024 mg/kg) produced short-acting (30 min) depression of locomotor activity. ADB-FUBINACA (ED 50 = 0.19 mg/kg), and AMB- FUBINACA (ED 50 = 0.19 mg/kg) depressed locomotor activity for 60–90 min; whereas MDMB-FUBINACA (ED 50 = 0.04 mg/kg) depressed locomotor activity for 150 min. AMB-FUBINACA produced tremors at the highest dose tested. 5F-MDMB-PINACA (ED 50 = 0.07), MDMB-CHIMICA (ED 50 = 0.01 mg/kg), MDMB-FUBINACA (ED 50 = 0.051 mg/kg), ADB-FUBINACA (ED 50 = 0.075 mg/kg) and AMB-FUBINACA (ED 50 = 0.029) fully substituted for the discriminative stimulus effects of Δ 9 -THC following 15-min pretreatment. All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ 9 -THC, which suggests they may have abuse liability similar to that of Δ 9 -THC. AMB-FUBINACA may have an increased risk of toxicities in recreational users.

Original languageEnglish
Pages (from-to)72-79
Number of pages8
JournalNeuroToxicology
Volume70
DOIs
StatePublished - 1 Jan 2019

Fingerprint

Dronabinol
Cannabinoids
Locomotion
Drug Legislation
Cannabis
Drug and Narcotic Control
Toxicity
Rats
Hematologic Tests
Tremor
Blood
Pharmaceutical Preparations

Keywords

  • Abuse liability
  • Drug discrimination
  • Locomotor activity
  • Mouse
  • Rat

Cite this

@article{e17522739fdd4231bb47aa9235d81a49,
title = "Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids",
abstract = "A new generation of novel cannabinoid compounds have been developed as marijuana substitutes to avoid drug control laws and cannabinoid blood tests. 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liability. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Discriminative stimulus effects were tested in rats trained to discriminate Δ 9 -tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (ED 50 = 1.1 mg/kg) and MDMB-CHIMICA (ED 50 = 0.024 mg/kg) produced short-acting (30 min) depression of locomotor activity. ADB-FUBINACA (ED 50 = 0.19 mg/kg), and AMB- FUBINACA (ED 50 = 0.19 mg/kg) depressed locomotor activity for 60–90 min; whereas MDMB-FUBINACA (ED 50 = 0.04 mg/kg) depressed locomotor activity for 150 min. AMB-FUBINACA produced tremors at the highest dose tested. 5F-MDMB-PINACA (ED 50 = 0.07), MDMB-CHIMICA (ED 50 = 0.01 mg/kg), MDMB-FUBINACA (ED 50 = 0.051 mg/kg), ADB-FUBINACA (ED 50 = 0.075 mg/kg) and AMB-FUBINACA (ED 50 = 0.029) fully substituted for the discriminative stimulus effects of Δ 9 -THC following 15-min pretreatment. All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ 9 -THC, which suggests they may have abuse liability similar to that of Δ 9 -THC. AMB-FUBINACA may have an increased risk of toxicities in recreational users.",
keywords = "Abuse liability, Drug discrimination, Locomotor activity, Mouse, Rat",
author = "Gatch, {Michael B.} and Forster, {Michael J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.neuro.2018.11.004",
language = "English",
volume = "70",
pages = "72--79",
journal = "NeuroToxicology",
issn = "0161-813X",
publisher = "Elsevier",

}

Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids. / Gatch, Michael B.; Forster, Michael J.

In: NeuroToxicology, Vol. 70, 01.01.2019, p. 72-79.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids

AU - Gatch, Michael B.

AU - Forster, Michael J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A new generation of novel cannabinoid compounds have been developed as marijuana substitutes to avoid drug control laws and cannabinoid blood tests. 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liability. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Discriminative stimulus effects were tested in rats trained to discriminate Δ 9 -tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (ED 50 = 1.1 mg/kg) and MDMB-CHIMICA (ED 50 = 0.024 mg/kg) produced short-acting (30 min) depression of locomotor activity. ADB-FUBINACA (ED 50 = 0.19 mg/kg), and AMB- FUBINACA (ED 50 = 0.19 mg/kg) depressed locomotor activity for 60–90 min; whereas MDMB-FUBINACA (ED 50 = 0.04 mg/kg) depressed locomotor activity for 150 min. AMB-FUBINACA produced tremors at the highest dose tested. 5F-MDMB-PINACA (ED 50 = 0.07), MDMB-CHIMICA (ED 50 = 0.01 mg/kg), MDMB-FUBINACA (ED 50 = 0.051 mg/kg), ADB-FUBINACA (ED 50 = 0.075 mg/kg) and AMB-FUBINACA (ED 50 = 0.029) fully substituted for the discriminative stimulus effects of Δ 9 -THC following 15-min pretreatment. All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ 9 -THC, which suggests they may have abuse liability similar to that of Δ 9 -THC. AMB-FUBINACA may have an increased risk of toxicities in recreational users.

AB - A new generation of novel cannabinoid compounds have been developed as marijuana substitutes to avoid drug control laws and cannabinoid blood tests. 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liability. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Discriminative stimulus effects were tested in rats trained to discriminate Δ 9 -tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (ED 50 = 1.1 mg/kg) and MDMB-CHIMICA (ED 50 = 0.024 mg/kg) produced short-acting (30 min) depression of locomotor activity. ADB-FUBINACA (ED 50 = 0.19 mg/kg), and AMB- FUBINACA (ED 50 = 0.19 mg/kg) depressed locomotor activity for 60–90 min; whereas MDMB-FUBINACA (ED 50 = 0.04 mg/kg) depressed locomotor activity for 150 min. AMB-FUBINACA produced tremors at the highest dose tested. 5F-MDMB-PINACA (ED 50 = 0.07), MDMB-CHIMICA (ED 50 = 0.01 mg/kg), MDMB-FUBINACA (ED 50 = 0.051 mg/kg), ADB-FUBINACA (ED 50 = 0.075 mg/kg) and AMB-FUBINACA (ED 50 = 0.029) fully substituted for the discriminative stimulus effects of Δ 9 -THC following 15-min pretreatment. All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ 9 -THC, which suggests they may have abuse liability similar to that of Δ 9 -THC. AMB-FUBINACA may have an increased risk of toxicities in recreational users.

KW - Abuse liability

KW - Drug discrimination

KW - Locomotor activity

KW - Mouse

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=85056624262&partnerID=8YFLogxK

U2 - 10.1016/j.neuro.2018.11.004

DO - 10.1016/j.neuro.2018.11.004

M3 - Article

VL - 70

SP - 72

EP - 79

JO - NeuroToxicology

JF - NeuroToxicology

SN - 0161-813X

ER -